Recently, somatic mutations of EGFR and BRAF and gene rearrangements of ALK and ROS1 have been recommended for testing before the initial treatment of patients with advanced non-small cell lung cancer (NSCLC) based on the guidelines from major professional organizations [1,2,3,4,5]. Here, ALK is linked to non-small cell lung carcinoma.